Projekt
Skippain
Abgeschlossen · 2018 bis 2019
Hutz Carina Liane, Forrer Silvia, Bartz-Batliner Mira, Rubbert-Roth Andrea
Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Abgeschlossen
Start
2018
Ende
2019
Finanzierungsart
Industrie
Studiendesign
This is a 24-week, randomized, double-blind, placebo-controlled, multicenter study to
evaluate the efficacy and safety of secukinumab in controlling spinal pain in patients with
axSpA. The study will consist of 2 treatment periods: a double-blind, placebo-controlled
period from Baseline to Week 8 (i.e. Treatment Period 1) and a double-blind secukinumab
treatment period from Week 8 to Week 24 (i.e. Treatment Period 2). At Baseline, patients will
be randomized to either secukinumab 150 mg or placebo. At Week 8, patients will be
re-randomized to 1 of 5 treatment arms to receive either secukinumab 150 mg or secukinumab
300 mg.
Schlagwörter (Tags)
spinal pain in patients with axSPA, secukinumab
Kurzbeschreibung/Zielsetzung
SKIPPAIN (Speed of onset of SecuKinumab-Induced relief
from Pain in Patients with AxIal SpoNdyloarthritis)
A 24-week, randomized, double-blind, placebo-controlled,
multicenter study to evaluate the efficacy and safety of
secukinumab in controlling spinal pain in patients with
axial spondyloarthritis